Boston Scientific Exceeds Q2 Earnings and Revenue Expectations
Boston Scientific (NYSE:BSX) reported second-quarter earnings of $0.86 per share, exceeding the consensus estimate of $0.83. The company's revenue rose to $5.44 billion, surpassing expectations of $5.37 billion and reflecting 7% operational growth across its business segments. Both core divisions—MedSurg and Cardiovascular—posted strong results, with MedSurg reporting a 5.9% sales increase and Cardiovascular achieving an 8.3% rise in net sales. International markets also contributed significantly to the revenue boost, particularly Asia-Pacific (11.2%) and Latin America/Canada (22.4%). Despite strong Q2 performance, Boston Scientific's updated full-year guidance fell short of market expectations. The company now forecasts earnings per share between $3.28 and $3.32 for the year versus a consensus estimate of $3.36.
Tickers: $BSX
Topics: Financial Performance Medical Devices